Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Progress and challenges in anti-obesity pharmacotherapy
Daniel H. Bessesen, Luc F. Van Gaal
The Lancet Diabetes & Endocrinology (2017) Vol. 6, Iss. 3, pp. 237-248
Closed Access | Times Cited: 296

Showing 26-50 of 296 citing articles:

Urolithin A exerts antiobesity effects through enhancing adipose tissue thermogenesis in mice
Bo Xia, Xiaochen Shi, Baocai Xie, et al.
PLoS Biology (2020) Vol. 18, Iss. 3, pp. e3000688-e3000688
Open Access | Times Cited: 113
Pomegranate polyphenols and urolithin A inhibit α-glucosidase, dipeptidyl peptidase-4, lipase, triglyceride accumulation and adipogenesis related genes in 3T3-L1 adipocyte-like cells
Francisco Les, José M. Arbones-Mainar, Marta Sofía Valero, et al.
Journal of Ethnopharmacology (2018) Vol. 220, pp. 67-74
Closed Access | Times Cited: 110
Phytochemicals as Anti-Inflammatory Agents in Animal Models of Prevalent Inflammatory Diseases
Seong A. Shin, Byeong Jun Joo, Jun Seob Lee, et al.
Molecules (2020) Vol. 25, Iss. 24, pp. 5932-5932
Open Access | Times Cited: 110
Oil-in-water Pickering emulsions via microfluidization with cellulose nanocrystals: 2. In vitro lipid digestion
Long Bai, Shanshan Lv, Wenchao Xiang, et al.
Food Hydrocolloids (2019) Vol. 96, pp. 709-716
Open Access | Times Cited: 109
Comprehensive Review of Current and Upcoming Anti-Obesity Drugs
Jang Won Son, Sungrae Kim
Diabetes & Metabolism Journal (2020) Vol. 44, Iss. 6, pp. 802-818
Open Access | Times Cited: 107
Glucagon‐like peptide‐1 receptor agonists for antipsychotic‐associated cardio‐metabolic risk factors: A systematic review and individual participant data meta‐analysis
Dan Siskind, Margaret Hahn, Christoph U. Correll, et al.
Diabetes Obesity and Metabolism (2018) Vol. 21, Iss. 2, pp. 293-302
Closed Access | Times Cited: 101
The challenge for global health systems in preventing and managing obesity
Luke Wolfenden, Majid Ezzati, Bagher Larijani, et al.
Obesity Reviews (2019) Vol. 20, Iss. S2, pp. 185-193
Open Access | Times Cited: 91
Anti-Obesity Effects of Medicinal and Edible Mushrooms
Kumar Ganesan, Baojun Xu
Molecules (2018) Vol. 23, Iss. 11, pp. 2880-2880
Open Access | Times Cited: 87
Factors affecting weight loss variability in obesity
Robert Dent, Ruth McPherson, Mary‐Ellen Harper
Metabolism (2020) Vol. 113, pp. 154388-154388
Closed Access | Times Cited: 87
Pediatric obesity: Current concepts
Donald E. Greydanus, Marisha Agana, Manmohan K. Kamboj, et al.
Disease-a-Month (2018) Vol. 64, Iss. 4, pp. 98-156
Closed Access | Times Cited: 86
Gastrointestinal tolerability of once‐weekly semaglutide 2.4 mg in adults with overweight or obesity, and the relationship between gastrointestinal adverse events and weight loss
Sean Wharton, Salvatore Calanna, Melanie J. Davies, et al.
Diabetes Obesity and Metabolism (2021) Vol. 24, Iss. 1, pp. 94-105
Open Access | Times Cited: 83
Effects of time-restricted feeding on body weight, body composition and vital signs in low-income women with obesity: A 12-month randomized clinical trial
Isabele Rejane de Oliveira Maranhão Pureza, André Eduardo da Silva Júnior, Dafiny Rodrigues Silva Praxedes, et al.
Clinical Nutrition (2020) Vol. 40, Iss. 3, pp. 759-766
Closed Access | Times Cited: 74
Semaglutide improves cardiometabolic risk factors in adults with overweight or obesity: STEP 1 and 4 exploratory analyses
Mikhail Kosiborod, Meena Bhatta, Melanie J. Davies, et al.
Diabetes Obesity and Metabolism (2022) Vol. 25, Iss. 2, pp. 468-478
Open Access | Times Cited: 61
Efficacy and safety of once-weekly semaglutide in adults with overweight or obesity: a meta-analysis
Ping Zhong, Hai Zeng, Miaochun Huang, et al.
Endocrine (2022) Vol. 75, Iss. 3, pp. 718-724
Closed Access | Times Cited: 54
Efficacy and safety of semaglutide on weight loss in obese or overweight patients without diabetes: A systematic review and meta-analysis of randomized controlled trials
Xueqin Gao, Xiaoli Hua, Xu Wang, et al.
Frontiers in Pharmacology (2022) Vol. 13
Open Access | Times Cited: 52
What is clinically relevant weight loss for your patients and how can it be achieved? A narrative review
Deborah B. Horn, Jaime P. Almandoz, Michelle Look
Postgraduate Medicine (2022) Vol. 134, Iss. 4, pp. 359-375
Open Access | Times Cited: 50
Randomized controlled trial for time-restricted eating in overweight and obese young adults
Limin Zhang, Zhan Liu, Jiaqi Wang, et al.
iScience (2022) Vol. 25, Iss. 9, pp. 104870-104870
Open Access | Times Cited: 46
The Benefits of Anthocyanins against Obesity-Induced Inflammation
Chanya Ngamsamer, Jintana Sirivarasai, Nareerat Sutjarit
Biomolecules (2022) Vol. 12, Iss. 6, pp. 852-852
Open Access | Times Cited: 42
Approved Anti-Obesity Medications in 2022 KSSO Guidelines and the Promise of Phase 3 Clinical Trials: Anti-Obesity Drugs in the Sky and on the Horizon
Eon Ju Jeon, Kiyoung Lee, Kyoung Kon Kim
Journal of Obesity & Metabolic Syndrome (2023) Vol. 32, Iss. 2, pp. 106-120
Open Access | Times Cited: 22
Semaglutide 2.4 mg clinical outcomes in patients with obesity or overweight in a real‐world setting: A 6‐month retrospective study in the United States (SCOPE)
Aleksandrina Ruseva, Wojciech Michalak, Zhenxiang Zhao, et al.
Obesity Science & Practice (2024) Vol. 10, Iss. 1
Open Access | Times Cited: 13
Comparative efficacy of exercise, diet and/or pharmacological interventions on BMI, ovulation, and hormonal profile in reproductive-aged women with overweight or obesity: a systematic review and network meta-analysis
David Ruiz‐González, Iván Cavero‐Redondo, Alba Hernández‐Martínez, et al.
Human Reproduction Update (2024) Vol. 30, Iss. 4, pp. 472-487
Open Access | Times Cited: 12
Inequalities in the provision of GLP-1 receptor agonists for the treatment of obesity
Stephanie W. Waldrop, Veronica R. Johnson, Fatima Cody Stanford
Nature Medicine (2024) Vol. 30, Iss. 1, pp. 22-25
Closed Access | Times Cited: 11
Semaglutide alleviates gut microbiota dysbiosis induced by a high-fat diet
Xinhao Duan, Lei Zhang, Yi Liao, et al.
European Journal of Pharmacology (2024) Vol. 969, pp. 176440-176440
Closed Access | Times Cited: 8
Utilization of Anti-obesity Medications After Bariatric Surgery: Analysis of a Large National Database
Stephen A. Firkins, Vibhu Chittajallu, Bailey Flora, et al.
Obesity Surgery (2024) Vol. 34, Iss. 5, pp. 1415-1424
Closed Access | Times Cited: 8
Nanotechnology advances towards development of targeted-treatment for obesity
Nicole Remaliah Samantha Sibuyi, Koena Leah Moabelo, Mervin Meyer, et al.
Journal of Nanobiotechnology (2019) Vol. 17, Iss. 1
Open Access | Times Cited: 73

Scroll to top